Score Overview
UroGen Pharma Ltd fundamental performance
Between 2020 and 2025, revenue grew from $ 11M to $ 109M and net income went from -$ 128M to -$ 153M. Revenue increased in every one of those 5 years; net income in 3.
Across UroGen Pharma Ltd's full reported history, from 2017 to 2025, revenue grew from $ 8M to $ 109M and net income went from -$ 20M to -$ 153M. Revenue increased in 78% of the years measured; net income in 44%.
UroGen Pharma Ltd currently holds a 5-year HDB Score of 6.2 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-13 | $ 48.12 | — |
1 Year2025-08-13 | $ 20.11 | 139.28% |
5 Years2021-08-13 | $ 15.13 | 218.04% |
All Time2017-05-04 | $ 13.98 | 244.21% |
| Period | Last Price2026-08-13 | 1 Year2025-08-13 | 5 Years2021-08-13 | All Time2017-05-04 |
|---|---|---|---|---|
| Price | $ 48.12 | $ 20.11 | $ 15.13 | $ 13.98 |
| Return | — | 139.28% | 218.04% | 244.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 188M | -$ 97M | $ 107M |
| 2025 | $ 109M | -$ 153M | $ 120M |
| 2024 | $ 90M | -$ 126M | $ 236M |
| 2023 | $ 82M | -$ 102M | $ 136M |
| 2022 | $ 64M | -$ 109M | $ 99M |
| 2021 | $ 48M | -$ 110M | $ 89M |
| 2020 | $ 11M | -$ 128M | $ 102M |
| 2019 | $ 18K | -$ 105M | $ 147M |
| 2018 | $ 1M | -$ 75M | $ 101M |
| IPO2017 | $ 8M | -$ 20M | $ 73M |
Explore beyond URGN
You're looking at UroGen Pharma Ltd. Members apply the same fundamental framework across all 3,859 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,859 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
